We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Glutamine for the Treatment of Patients With Irritable Bowel Syndrome (AT005291)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01414244
Recruitment Status : Completed
First Posted : August 11, 2011
Results First Posted : August 9, 2017
Last Update Posted : August 9, 2017
Information provided by (Responsible Party):
Nicholas Verne, Tulane University

Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Triple (Participant, Care Provider, Investigator);   Primary Purpose: Treatment
Condition: Diarrhea-Predominant Irritable Bowel Syndrome
Intervention: Drug: Glutamine

  Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
Glutamine Oral Glutamine Powder
Placebo Oral Whey Protein Powder

Participant Flow:   Overall Study
    Glutamine   Placebo
STARTED   54   52 
COMPLETED   54   52 

  Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
Glutamine Oral Glutamine Powder
Placebo Oral Whey Protein Powder
Total Total of all reporting groups

Baseline Measures
   Glutamine   Placebo   Total 
Overall Participants Analyzed 
[Units: Participants]
 54   52   106 
[Units: Years]
Mean (Standard Deviation)
 32.4  (9.5)   30.9  (7.1)   31.7  (8.3) 
Sex: Female, Male 
[Units: Participants]
Count of Participants
Female      37  68.5%      37  71.2%      74  69.8% 
Male      17  31.5%      15  28.8%      32  30.2% 
Region of Enrollment 
[Units: Participants]
Count of Participants
United States   54   52   106 

  Outcome Measures

1.  Primary:   Change in the Irritable Bowel Symptom Severity Scale   [ Time Frame: baseline and 8 weeks following therapy ]

2.  Secondary:   Intestinal Permeability   [ Time Frame: baseline and 8 weeks following therapy ]

3.  Secondary:   Stool Frequency   [ Time Frame: Baseline and 8 weeks following therapy ]

4.  Secondary:   Stool Consistency   [ Time Frame: Baseline and 8 weeks following therapy ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

  More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

Results Point of Contact:  
Name/Title: QiQi Zhou
Organization: Tulane University
phone: 988-7800
e-mail: qiqi06@gmail.com

Responsible Party: Nicholas Verne, Tulane University
ClinicalTrials.gov Identifier: NCT01414244     History of Changes
Other Study ID Numbers: 11-271
First Submitted: July 29, 2011
First Posted: August 11, 2011
Results First Submitted: April 10, 2017
Results First Posted: August 9, 2017
Last Update Posted: August 9, 2017